Scienture Holdings (SCNX) H.C. Wainwright 28th Annual Global Investment Conference summary

Business strategy and commercial focus

• Focuses on differentiated therapies by improving established molecules and launching follow-on brands.

• Two products launched in 2026, with additional products in the pipeline for the next few years.

• Uses data-driven strategies for product selection, R&D, and targeted commercial efforts.

• Comprehensive commercial infrastructure includes payer contracting, distribution, and a growing field force.

• Actively seeks inorganic growth through partnerships or acquisitions.

Product portfolio and pipeline

• Arbli, a room temperature stable losartan oral suspension, addresses a significant market gap for hypertension patients needing liquid formulations.

• REZENOPY, a 10 mg nasal spray for opioid overdose, targets a niche segment requiring higher doses than standard Narcan.

• Pipeline includes a migraine pen injector (NDA filing expected by end of 2027), a biosimilar for stroke and CVAD indications, and a long-acting non-opioid pain injection.

• All programs are protected by strong intellectual property, with innovations in formulation and delivery.

• Products are developed in-house with strategic global partners for R&D, manufacturing, and regulatory support.

Market positioning and growth

• Products are gaining traction with healthcare providers, institutions, and payers, including coverage from major national and government plans.

• Commercial operations span hospitals, clinics, long-term care, and virtual sales, with expansion across 10 territories.

• Revenue growth is driven by product launches, expanded formulary access, and increased patient reach.

• Financial position is stable, with sufficient liquidity and a clean balance sheet.

• Ongoing efforts to scale commercial platform and add new revenue-generating assets.